Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) EBT Margin (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed EBT Margin for 8 consecutive years, with 37.14% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 20671.0% year-over-year to 37.14%, compared with a TTM value of 81.39% through Dec 2025, up 46314.0%, and an annual FY2025 reading of 81.39%, up 46314.0% over the prior year.
  • EBT Margin was 37.14% for Q4 2025 at Zevra Therapeutics, up from 3.74% in the prior quarter.
  • Across five years, EBT Margin topped out at 296.95% in Q2 2025 and bottomed at 51577.08% in Q2 2022.
  • Average EBT Margin over 5 years is 2730.21%, with a median of 98.38% recorded in 2022.
  • The sharpest move saw EBT Margin plummeted -5162884bps in 2022, then surged 5154583bps in 2023.
  • Year by year, EBT Margin stood at 103.37% in 2021, then skyrocketed by 370bps to 278.96% in 2022, then plummeted by -155bps to 153.96% in 2023, then fell by -10bps to 169.56% in 2024, then soared by 122bps to 37.14% in 2025.
  • Business Quant data shows EBT Margin for ZVRA at 37.14% in Q4 2025, 3.74% in Q3 2025, and 296.95% in Q2 2025.